Clinical Trial Update: Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC [Phase 1, Phase 2]

View source ↗

Summary

An early-phase clinical trial evaluating anti-MUC1 CAR T cells in combination with PD-1 knockout engineered T cells for non-small cell lung cancer; current stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-MUC1 CAR T Cells
• PD-1 Knockout Engineered T Cells

Snippet

Sponsor: The First Affiliated Hospital of Guangdong Pharmaceutical University | Conditions: Lung Neoplasm Malignant, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN